|
Adriamycin will never be abandoned for about half of Her2+ women (regardless of hormone status) because about half of Her2+ women are also TopIIA positive (although it is not routinely tested right now, it will be) and adriamycin really knocks down and kills TopIIA positive bc. Therefore, about half the women who are Her2+ will get AC followed by TH and the others will get TCH (Taxol or taxotere with carboplatin and herceptin).
This is the wave of the future - better tumor marker testing so you only get the drugs that will work the best on your tumor and avoid others that don't do anything to the cancer.
Kind regards
Becky
|